Trial phases and randomization

In one sentence

Trial phases describe the questions a treatment study asks, while randomization assigns participants by chance to make treatment groups more comparable.

The intuition

Think of developing a new treatment as asking a sequence of questions. Can people receive it safely? Does it show useful activity? Does it improve outcomes compared with another approach?

The phase tells you roughly which question a study emphasizes. Randomization tells you how it forms comparison groups. Neither word, by itself, tells you whether this person can join or will benefit.

How it works

Cancer treatment trials often move through these phases. A protocol is the study's written plan. Its actual design matters more than a phase label alone.

Phase	Main teaching question	What the label does not promise
1	How should this treatment be given, and what harms appear?	Proven benefit or absence of serious toxicity
2	Is there enough activity in this population to study further?	Better outcomes than another treatment
3	How does it compare with a defined alternative?	That the new treatment wins
4	What do we learn about an approved treatment during broader use?	That every investigated use is approved

Some studies combine phases. Some phase 2 studies are randomized; some studies have one treatment group. Look for the actual comparison and the outcome being measured.

Randomization uses chance to assign eligible, consenting participants to study groups. It reduces the risk that human choices place healthier people in one group. It can also help balance factors researchers did not measure. Chance can still leave imbalances, especially in small studies.

Blinding is a separate design feature: keeping participants, staff or outcome assessors unaware of assignment when feasible. It can reduce differences in care or assessment. Randomization does not automatically make a study blinded.

Researchers should report how assignment was performed and how outcomes were analyzed. Dropout, missing assessments, treatment changes and unequal follow-up can complicate the result even after a sound assignment process.

Why it matters in cancer

A patient may enter a randomized trial without being assigned the experimental treatment. The control could be standard care, standard care plus a placebo, or another specified approach. Read the protocol rather than assuming the control means no treatment.

A single-arm study can reveal meaningful activity and harms. It is less able to separate treatment effects from selection, natural history and other care. That does not make it worthless; it changes the claim it can support.

Worked example

A fictional early study treats volunteers with Drug A. Their tumors shrink, but no comparison group receives the usual therapy. This supports studying activity. It does not show that Drug A improves survival more than usual therapy.

A later randomized study assigns eligible volunteers to Drug A plus usual therapy or usual therapy alone. That design can test the added treatment's effect, provided its conduct and analysis are sound. A particular volunteer still cannot choose the group.

Common confusions

A higher phase is not an individual benefit score.
Random assignment and random sampling are different. Trial volunteers are still a selected population.
A trial listed as recruiting may have no open local slot for the relevant cohort.
A promising phase 1 signal is neither a drug approval nor proof in another cancer setting.

Sources and scope

Source check: October 9, 2026. Examples are fictional; no trial outcomes or enrollment promises are implied. Expert and learner review remain pending.

National Cancer Institute: how clinical trials work — phases, randomization and controls.
FDA: clinical research in the drug-development process — phase questions and study design.
National Cancer Institute: clinical trial protocol — the plan that defines a particular trial.